| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TScan Therapeutics, Inc.$1.09
+0.03 (+2.83%)
D 27Pipeline Score Richly Valued Biotech · Commercial
Market Cap
69.27 M
EPS
-0.96
P/E Ratio
-
Value Trade
432.01 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
982.00 K
R&D Expenses
21.90 M
Operating CF
-24.28 M
Total Assets
201.99 M
Total Liabilities
105.07 M
Equity
96.92 M
D/E Ratio
12,345
-1.85 %
Week
-17.19 %
1 Month
4.95 %
3 Month
8.16 %
6 Month
-91.17 %
5 Year
-91.17 %
All Time
Cash Data
Cash Position
128.06 M
Monthly Burn
8.09 M
Runway
13.9 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
968.75 K
52 Week Range
0.88 - 2.57
% held by Insiders
14.15 %
% held by Institutions
47.86 %
Enterprise Value
33.75 M
Total Shares
61.09 M
Short %
1.4 %
Float Shares
50.64 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for TScan Therapeutics, Inc.
456Total events
5Upcoming
52Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
Event history 451
Q3 2026
◆Trial InitiationTSC-102Trial
Plans to initiate Phase 1 trial for TSC-102-A01
hematologic malignanciessource ↗
Q3 2026
◆Trial InitiationTSC-102Trial
Plans to initiate Phase 1 trial for TSC-102-A03
hematologic malignanciessource ↗
Jun 30, 2026
◆Oral PresentationPresentation
TScan Therapeutics to participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference fireside chat
Jun 22, 2026
◆Oral PresentationPresentation
Virtual KOL event featuring Ran Reshef to discuss Cohort C data and Phase 3 plans
Jun 22, 2026
▲Topline ReadoutTSC-101Clinical Data
Initial data from Cohort C of ALLOHA Phase 1 study
heme malignancies undergoing allogeneic hematopoietic cell transplantationsource ↗
Jun 3, 2026
▲Partnership / LicenseTSC-101Corporate
Cellares and TScan Therapeutics announce agreement to evaluate automated manufacturing of TSC-101
hematologic malignanciessource ↗
Jun 2026
◆Trial InitiationTSC-101Trial
First patient enrollment in Phase 3 ALLOHA-2 study
heme malignancies undergoing allogeneic hematopoietic cell transplantationsource ↗
May 12, 2026
◆Poster PresentationPresentation
Poster presentation at ASGCT 29th Annual Meeting: Novel CD45-targeted TCR-T cell therapies
cancersource ↗
May 11, 2026
◆Poster PresentationPresentation
Abstract accepted for poster presentation at ASGCT 29th Annual Meeting
Apr 15, 2026
◆Oral PresentationPresentation
TScan Therapeutics to participate in fireside chat at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Trial InitiationTSC-101Trial
Launch pivotal trial for TSC-101 in AML and MDS
acute myeloid leukemia and myelodysplastic syndromessource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $7M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankTScan Therapeutics, Inc. faces pipeline headwinds (27/100), with $130M risk-adjusted pipeline value, led by TSC-204-A0201 in Head and Neck Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSC-204-A0201 Monoclonal antibody | Head and Neck Cancer | Phase 1 | NCT05973487 | 9% | $130M | ACTIVE NOT_RECRUITING | 840 | VERY_FAST | C (45) | Dec 30, 2026 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TSC-101 RMAT | hematologic malignancies | Phase 1 | 2026-03-04 | TSC-101 was well-tolerated with no dose-limiting toxicities observed.; Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23); overall survival (HR=0.61; p=0.52); 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free compared to 1/4 (25%) in the control arm. Read More | TScan Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (unaudited, in thousands, except share amount) Read More | |
TSC-101 RMAT | hematologic malignancies | Phase 1 | 2026-03-04 | TSC-101 was well-tolerated with no dose-limiting toxicities observed.; Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23); overall survival (HR=0.61; p=0.52); 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free compared to 1/4 (25%) in the control arm. Read More | TScan Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (unaudited, in thousands, except share amount) Read More | |
TSC-101 RMAT | hematologic malignancies | Phase 1 | 2026-03-04 | TSC-101 was well-tolerated with no dose-limiting toxicities observed.; Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23); overall survival (HR=0.61; p=0.52); 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free compared to 1/4 (25%) in the control arm. Read More | TScan Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (unaudited, in thousands, except share amount) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TCRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TCRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TCRXTScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
TScan Therapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company will host a fireside chat at 11:30 a.m. Eastern Time, which will be available via webcast. TScan is developing TCR-engineered T cell therapies for cancer treatment, focusing on hematologic malignancies and solid tumors.
Read more →TCRX▼ -6%on this newsshared move
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101, showing that 11 of 14 patients achieved complete donor chimerism within approximately three weeks. The therapy was well-tolerated, and the company plans to enroll its first patient in the Phase 3 ALLOHA-2 study this month. The results support the efficacy of TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.
Read more →TCRXCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Cellares and TScan Therapeutics have entered into an agreement to evaluate the automated manufacturing of TSC-101, a treatment aimed at patients with hematologic malignancies. This collaboration seeks to enhance the production process of TSC-101, potentially improving access for patients. Further details on the implications of this partnership are yet to be disclosed.
Read more →TCRXTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics reported its Q1 2026 financial results, highlighting key milestones for its T cell receptor therapies. The company plans to initiate a Phase 3 study of TSC-101 and a Phase 1 study of TSC-102-A01 and TSC-102-A03 later this year. Despite a decrease in revenue and a net loss, TScan's cash reserves are expected to support operations into 2027.
Read more →TCRXTScan Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (unaudited, in thousands, except share amount)
TScan Therapeutics reported financial results for Q1 2026, highlighting significant advancements in its TCR-T therapy development for cancer. The company is preparing for multiple clinical trials, including a Phase 3 study for its lead candidate TSC-101 and two Phase 1 studies for TSC-102-A01 and TSC-102-A03. Initial data from their ALLOHA trial is expected in Q2 2026, emphasizing robust patient enrollment. However, the company faced a revenue decline compared to the previous year and reported a net loss for the quarter, although it has enough cash reserves to sustain operations until late 2027.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics has announced the acceptance of an abstract for a poster presentation at the ASGCT 29th Annual Meeting, scheduled for May 11-15 in Boston. The presentation will focus on novel CD45-targeted TCR-T cell therapies aimed at eliminating residual disease and preventing relapse after allogeneic hematopoietic cell transplantation. The company plans to share the presentation materials on its website post-event.
Read more →TCRXTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
TScan Therapeutics, a clinical-stage biotech company, will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The event will feature a fireside chat at 3:00 p.m. Eastern Time, with a webcast available on the company's website. TScan is focused on developing TCR-engineered T cell therapies for cancer treatment.
Read more →TCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its hematologic malignancies program. The company presented positive data from the ALLOHA Phase 1 heme trial and received FDA clearance for two new TCR-T therapy candidates. Despite a net loss, TScan's financial position remains strong, with sufficient cash to support operations into 2027.
Read more →TCRXTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics has completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial, utilizing a new commercial-ready manufacturing process. The FDA has cleared IND applications for two new candidates, TSC-102-A01 and TSC-102-A03, which target specific HLA types. The company plans to initiate a Phase 1 study for these candidates in the latter half of 2026, aiming to expand its treatment options for hematologic malignancies.
Read more →TCRX▲ +5.7%on this newsshared move
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
TScan Therapeutics, a clinical-stage biotech firm, will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The event will include a hybrid presentation and an analyst-led Q&A session. TScan focuses on developing T cell receptor-engineered therapies for cancer, with ongoing trials for hematologic malignancies and solid tumors.
Read more →TCRXDisclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but n
TScan Therapeutics has presented forward-looking statements about its clinical programs and upcoming plans. The company highlights promising data from its TCR-T therapy candidate, TSC-101, which shows durable responses among patients. TScan also aims to launch a pivotal study for TSC-101 in Q2 2026 and expand its market opportunities with additional IND submissions. The report emphasizes the need for continued monitoring of risks associated with developing innovative therapies.
Read more →TCRX▼ -7.4%on this news
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics reported positive updated data from its ALLOHA Phase 1 trial for TSC-101 at the ASH Annual Meeting. The treatment demonstrated significant improvements in relapse-free and overall survival rates among patients with hematologic malignancies. Notably, all patients who reached a two-year follow-up remained relapse-free. The company plans to initiate a pivotal study in 2026.
Read more →TCRX▲ +6.9%on this newsshared move
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
TScan Therapeutics will host a virtual KOL event on December 8 to discuss updates from the ALLOHA Phase 1 trial and future market opportunities for its TCR-T therapies. The event will highlight two-year relapse data from the trial and the company's enhanced manufacturing process. The discussion will also cover the unmet medical needs in hematologic malignancies.
Read more →TCRXTScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics reported its Q3 2025 financial results, highlighting a productive FDA meeting that established a pivotal trial design for TSC-101. The company is prioritizing its heme malignancies program while also developing TCR-T therapies for solid tumors. Despite a net loss increase, TScan's cash position is strong, expected to support operations through mid-2027.
Read more →TCRXTScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TScan Therapeutics will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025. The event will feature a fireside chat, and a webcast will be available for those unable to attend. TScan is known for its TCR-engineered therapies aimed at treating cancer and preventing relapse in patients.
Read more →TCRX▼ -36.1%on this newsshared move
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
TScan Therapeutics has reached a positive agreement with the FDA on the pivotal study design for TSC-101, focusing on acute myeloid leukemia and myelodysplastic syndromes. The company is prioritizing its heme program while pausing enrollment in its solid tumor trial. A workforce reduction of approximately 30% has been enacted to extend the cash runway into the second half of 2027.
Read more →TCRX▼ -7%on this news
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
TScan Therapeutics announced the acceptance of two abstracts for presentation at the American College of Rheumatology Convergence 2025. One abstract will be presented orally, focusing on T-cell targets in Ankylosing Spondylitis, while the other will be a poster presentation on autoantigens in Scleroderma and Ulcerative Colitis. These findings highlight the potential of TScan's TargetScan technology in autoimmune disorders.
Read more →TCRXCompany Presentation September 2025 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking TScan's plans relating to developing and commercializing its TCR-T
TScan is focused on developing and commercializing its TCR-T therapy candidates with an emphasis on addressing solid tumors and hematologic malignancies. The company highlighted potential market opportunities and outlined its plans for preclinical studies and clinical trials. However, it noted the risks associated with forward-looking statements that may affect actual outcomes compared to expectations. Upcoming data presentations are expected to provide insights into the efficacy of their therapies.
Read more →TCRX▲ +6.9%on this news
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics, a clinical-stage biotech firm, announced its participation in upcoming investor conferences. The company focuses on T cell receptor-engineered therapies for cancer treatment and is actively enrolling patients in its clinical trials for hematologic malignancies and solid tumors. Webcasts of the events will be available on their website.
Read more →TCRXTScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Two-year relapse data from ALLOHA Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patient
TScan Therapeutics has reported its financial results for the second quarter of 2025, indicating a revenue increase to $3.1 million, largely due to research activities with Amgen. The company anticipates dosing its first solid tumor patients with multiplex TCR-T therapies in the third quarter of 2025, while also planning to present two-year relapse data from its ALLOHA Phase 1 trial by year-end. Despite a net loss increase to $37 million and rising R&D expenses, TScan's cash position allows operations to be funded until early 2027.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, a clinical-stage biotech firm, will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will focus on their TCR-engineered T cell therapies aimed at treating cancer. A webcast of the event will be available for those unable to attend live. The company is currently enrolling patients in its clinical trials.
Read more →TCRX▼ -9.3%on this news
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Updates from the PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials anticipated by end of year On-track to file IND a
TScan Therapeutics has reported its financial results for Q1 2025, showing a substantial increase in revenue compared to the previous year. The company remains focused on advancing its TCR-engineered T cell therapies, with significant updates expected from ongoing clinical trials by the end of the year. In addition, TScan appointed Stephen Camiolo as Senior VP of Market Access to enhance its strategy. Despite the positive growth indicators, the rising net loss and expenses could pose financial challenges moving forward.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
TScan Therapeutics has announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, scheduled for May 13-17 in New Orleans. The presentation will focus on CD45 as a universal target for TCR-T cell therapy following allogeneic hematopoietic cell transplantation. This highlights the company's ongoing commitment to developing innovative therapies for cancer treatment.
Read more →TCRXTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
TScan Therapeutics will participate in the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The company focuses on TCR-engineered T cell therapies for cancer treatment, with ongoing clinical trials for hematologic malignancies and solid tumors. A webcast of the event will be available on their website.
Read more →TCRXTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
TScan Therapeutics announced the appointment of Stephen Camiolo as Senior Vice President of Market Access, bringing over 25 years of industry experience. Camiolo's background includes leading successful product launches, particularly in cell therapies, positioning TScan favorably as it prepares for a pivotal trial of TSC-101 aimed at treating residual disease in patients with various hematologic malignancies. The company remains focused on advancements in its clinical programs and aims to deliver impactful TCR-engineered therapies.
Read more →TCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Presented updated data from ongoing ALLOHA Phase 1 heme trial at the 66 th ASH Annual Meeting and Exposition IND
TScan Therapeutics has reported its fourth quarter and full-year 2024 financial results, highlighting promising updates from its clinical trials. The company presented data from the ALLOHA Phase 1 heme trial during the ASH Annual Meeting, demonstrating a low rate of relapse among treated patients. TScan's IND application for a new TCR targeting MAGE-A4 has been cleared, furthering the company's clinical ambition. Despite substantial net losses and decreased revenue, TScan secured $30 million through a direct offering to enhance its financial stability.
Read more →TCRX▲ +5.8%on this news
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
TScan Therapeutics, Inc. has announced its participation at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The company, which focuses on T cell receptor-engineered therapies for cancer, aims to present its advancements at this significant industry event. A webcast of the presentation will be available on their website, allowing for wider accessibility to their developments. TScan is actively enrolling patients in its clinical programs for hematologic malignancies and solid tumors.
Read more →TCRXTScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics, Inc. has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference scheduled for February 25, 2025. The event will include a fireside chat, which will be accessible via webcast on the company's website. TScan focuses on developing T cell receptor-engineered therapies aimed at treating cancers, with ongoing clinical trials for hematologic and solid tumors.
Read more →TCRX▲ +6.9%on this news
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics, Inc. has announced a $30 million registered direct offering at a 37% premium to its last closing stock price. The investment will be used to extend the company's operational funding into the first quarter of 2027. The offering is made possible through a securities purchase agreement with Lynx1 Capital Management, highlighting their continued support. The offering is anticipated to close on December 27, 2024, subject to customary conditions.
Read more →TCRXTScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank New non-dilutive structure replaces existing convertible facility maturing in 2026, and ext
TScan Therapeutics has announced the refinancing of its existing convertible debt with a new term loan from Silicon Valley Bank, totaling up to $52.5 million. This agreement replaces the previous convertible facility maturing in 2026 and provides an extended interest-only period, enhancing the company's financial flexibility. The first tranche of $32.5 million will be used primarily to pay off existing debt, while the remainder will serve general corporate needs. TScan expects this refinancing to sustain its operations and clinical development until at least late 2026.
Read more →TCRX▼ -28.2%on this news· ran to -39% by day 3
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition To date, event-free survival strongly fav
TScan Therapeutics announced it will present updated results from the ALLOHA Phase 1 trial at the 66th ASH Annual Meeting. The trial focuses on TSC-100 and TSC-101 for patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome undergoing hematopoietic cell transplantation. Preliminary results indicate a significant improvement in event-free survival and a promising safety profile with no observed dose-limiting toxicities. The company plans to launch a pivotal trial in the second half of 2025 following positive feedback from the FDA.
Read more →TCRX▼ -5.4%on this news· ran to -25% by day 3shared move
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics, Inc. has been recognized by The Boston Globe as one of the Top Places to Work in Massachusetts for three consecutive years. This recognition is based on an employee-based survey that evaluates various aspects of the workplace experience. TScan's CEO and Senior Vice President of Human Resources highlighted the company's commitment to employee satisfaction and its progress in cultivating a positive workplace culture. Additionally, TScan continues to focus on developing TCR-engineered T cell therapies for cancer treatment.
Read more →TCRXTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
TScan Therapeutics is hosting a virtual key opinion leader event on December 10, 2024, to discuss updates from its ALLOHA Phase 1 heme trial and the clinical development strategy for its hemotherapy program. The event will cover preliminary results of TSC-100 and TSC-101 treatments in patients with certain leukemias. Additionally, the company aims to outline its strategy for potential FDA registration based on recent feedback. This event underscores TScan's efforts in advancing its T cell receptor-engineered therapy initiatives.
Read more →TCRXTScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the 66 th American Society of Hematology (ASH) Annual Meeti
TScan Therapeutics reported its financial results for Q3 2024, highlighting progress in its clinical programs, particularly the ALLOHA Phase 1 heme trial. Notably, all 16 patients treated in the trial did not experience relapse, showing encouraging signs for the efficacy of their multiplex TCR-T therapies. The company has a strong cash position, expected to fund operations through 2026, despite experiencing a notable drop in revenue and an increase in net loss compared to the previous year. They plan to provide updates on their clinical trials, including upcoming presentations at the ASH Annual Meeting, which may yield additional positive data.
Read more →TCRXTScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics has announced that preliminary results from its ALLOHA Phase 1 trial of TSC-100 and TSC-101 will be presented at the 66th ASH Annual Meeting. The trial focuses on patients with AML, ALL, and MDS undergoing allogeneic hematopoietic cell transplantation. Results show all patients treated with TSC therapies were relapse-free with no dose limiting toxicities reported. The company continues to enroll patients for the ongoing trial and expects to share further updates at the conference.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics has announced the acceptance of three abstracts for poster presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting, scheduled for November 6-10 in Houston, TX. The abstracts include topics on MAGE-A4-specific TCR-T therapy candidates and a customized multiplexed TCR-T cell therapy addressing intra-tumor heterogeneity. These presentations highlight significant advancements in TCR-engineered T cell therapies aimed at improving cancer treatment options. Additionally, materials from these presentations will be available on the company's website following the event.
Read more →TCRXTScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic
TScan Therapeutics has reported its financial results for Q2 2024, highlighting progress in its cancer treatment programs. The FDA has granted RMAT designation for its TCR-T therapy candidates TSC-100 and TSC-101, which target hematologic malignancies. The company has also engaged a Contract Development and Manufacturing Organization to support upcoming trials. Despite a notable decrease in revenue year-over-year, TScan retains a strong cash position, expected to sustain operations until late 2026.
Read more →TCRX▼ -6.7%on this news· ran to -20% by day 3
TScan Therapeutics Announces Updates to its Board of Directors Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Steph
TScan Therapeutics has announced the appointment of Garry A. Nicholson to its Board of Directors, highlighting his extensive experience in oncology and regulatory affairs. Timothy Barberich is retiring from his position as Chair, with Stephen Biggar taking over the role. Nicholson's background includes significant leadership roles in several biopharmaceutical companies, which the CEO believes will benefit TScan's growth and clinical initiatives. This board change indicates a strategic shift that aligns with TScan's mission to develop cancer therapies.
Read more →TCRX▼ -6.4%on this newsshared move
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
TScan Therapeutics has received RMAT designation from the FDA for its lead TCR-T therapy candidates, TSC-100 and TSC-101, aimed at treating heme malignancies such as AML and ALL. This designation highlights the potential of these therapies to fill unmet medical needs in treating patients undergoing hematopoietic cell transplantation. The recent update from the ALLOHA trial shows promising results, with all treated patients remaining relapse-free. The RMAT designation also allows for a more streamlined collaboration with the FDA in the development process.
Read more →TCRXTScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatmen
TScan Therapeutics has reported its financial results for Q1 2024, highlighting key developments in its clinical pipeline. The company dosed the first patient in its Phase 1 trial for solid tumors and reported that all patients in its Phase 1 heme program remain relapse-free. Despite these advancements, the company's revenue fell to $0.6 million, and it recorded a net loss of $30.1 million. The successful conclusion of a public offering has provided TScan with a strong financial position to pursue its strategic goals through 2026.
Read more →TCRXTScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
TScan Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial evaluating its TCR-T therapy for solid tumors, specifically targeting the cancer-associated antigen PRAME. The trial signifies a significant milestone for the company, which aims to report initial data in 2024. The company is already preparing TCR-T products for additional patients and plans to expand its ImmunoBank to include various targets related to solid tumors. Key executives expressed enthusiasm over the potential benefits of their innovative multiplex TCR-T approach to address the challenges of tumor heterogeneity.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
TScan Therapeutics, Inc. has announced that two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology Annual Meeting, scheduled for May 31 to June 4 in Chicago. The presentations will cover a Phase 1 trial of their engineered T cell therapies, TSC-100 and TSC-101, aimed at eliminating residual disease after hematopoietic cell transplantation, as well as initial data from a first-in-human clinical trial for their multiplexed TCR-engineered therapy, T-Plex. The company continues to focus on advancing its innovative therapies for cancer treatment.
Read more →TCRXTScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
TScan Therapeutics, Inc. announced the partial exercise of the underwriters' over-allotment option for additional shares following its recent public offering. The offering, which closed on April 19, 2024, totaled approximately $167.8 million, bolstering the company's capital for the development of its T cell receptor-engineered therapies for cancer. The SEC has declared the registration statement effective, facilitating the sale of these shares. This move reflects investor confidence and interest in TScan's therapeutic advancements.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
TScan Therapeutics has announced the acceptance of one oral and four poster presentations for the upcoming ASGCT 27th Annual Meeting from May 7-11, 2024. The presentations will cover significant topics including the discovery of tumor-reactive TCRs and ongoing trials for novel TCR-T therapies. This recognition at a leading gene and cell therapy conference underscores TScan's position in advancing cancer treatment through innovative biopharmaceutical research. The presentations will be available on the company's website following the event.
Read more →TCRXTScan Therapeutics Announces Closing of Upsized Public Offering
TScan Therapeutics has announced the closing of its upsized public offering, comprising 2,472,581 shares at a price of $7.13 each, generating approximately $150.1 million in gross proceeds. This offering includes pre-funded warrants and grants underwriters a 30-day option for additional shares. The funds will support the company's operational plans extending to Q4 2026. The offering was facilitated by well-known financial institutions, indicating a strong market interest in TScan's therapies.
Read more →TCRX▼ -5.3%on this newsshared move
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
TScan Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering amounting to $150 million, involving 2,472,581 shares of common stock priced at $7.1300 each. Additionally, the company is offering pre-funded warrants to purchase further shares at a similar price. The gross proceeds from this offering, expected to close on or around April 19, 2024, will be utilized for general corporate purposes. This financial move is believed to bolster the company's capacity to fund operations through the fourth quarter of 2026.
Read more →TCRX▼ -7.3%on this newsshared move
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at
TScan Therapeutics has provided a clinical pipeline update, highlighting significant progress in its T cell receptor-engineered therapies for solid tumors and hematologic malignancies. Over 40 patients have completed biomarker testing, with about 60% qualifying for TCR-T therapies. The dosing of the first patients in the solid tumor program is expected to begin in early May. Meanwhile, all patients treated with TSC-100 or TSC-101 in the heme malignancies program are reported to be relapse-free with more than 10 months of follow-up.
Read more →TCRX▼ -7.3%on this newsshared move
TScan Therapeutics Announces Launch of $125 million Proposed Public Offering
TScan Therapeutics has announced a proposed underwritten public offering of $125 million for shares of its voting common stock. The offering is set to be managed by Morgan Stanley and TD Cowen, amongst others, and is subject to market and regulatory conditions. TScan intends to use the net proceeds for general corporate purposes. The registration statement related to the offering was recently declared effective by the SEC, but uncertainties remain regarding the successful completion of the offering.
Read more →TCRXTScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical
TScan Therapeutics has appointed Dr. Chrystal U. Louis as its Chief Medical Officer, bringing with her extensive expertise in hematology and oncology. Dr. Louis will replace Dr. Debora Barton, who is stepping down for personal reasons but will aid in the transition. This leadership change comes at a vital stage for TScan as it advances its clinical programs in both hematologic malignancies and solid tumors. The company aims to leverage Dr. Louis's experience to enhance its cell therapy initiatives.
Read more →TCRX▼ -10.1%on this news
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
TScan Therapeutics, Inc. has announced its upcoming presentation at the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 9, 2024. The company specializes in developing T cell receptor-engineered therapies aimed at treating cancer. During the presentation, they will discuss their lead TCR-T candidates and advancements in their ImmunoBank, which supports treatment customization for various cancers. A webcast of the event will be accessible online, along with an archived version post-event for 90 days.
Read more →TCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies
TScan Therapeutics has reported its fourth quarter and full year 2023 financial results, highlighting significant advancements in their clinical programs. They announced that all eight patients in the treatment arms of their Phase 1 heme malignancies study are relapse-free, with updated efficacy data presented at a recent medical conference. Additionally, TScan received FDA approval for two new investigational new drug applications, expanding their solid tumor program. The company anticipates initiating its Phase 1 solid tumor study soon and expects to share initial data in 2024.
Read more →TCRXTScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
TScan Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference scheduled for March 6, 2024. The discussion will provide insight into the company’s T cell receptor (TCR)-engineered therapies targeted at cancer treatment. An archived replay of the webcast will be available on the company's website for 30 days post-event, allowing wider accessibility to the information presented.
Read more →TCRXTScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan Therapeutics announced promising Phase 1 clinical trial results showcasing that all eight patients in the treatment arm using TSC-100 and TSC-101 achieved and maintained complete donor chimerism, remaining relapse-free. Notable outcomes included a patient with high-risk, TP53-mutated MDS continuing to be relapse-free for over a year after TSC-101 treatment. However, some challenges were observed in the control arm where two patients relapsed. TScan continues to evaluate these therapies, with further data expected as the trial progresses.
Read more →TCRXTScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan Therapeutics, Inc. is set to host a virtual key opinion leader event on February 26, 2024, to discuss updated results from its Phase 1 study on hematologic malignancies. The study has garnered recognition, being selected for a Best Abstracts Award at the upcoming Tandem Meetings. The event will focus on the implications of initial data relating donor chimerism to relapse risk and feature prominent speakers from the medical community. The company aims to provide detailed insights into its ongoing clinical trials and therapeutic approaches in combating cancer.
Read more →TCRX▲ +6.7%on this news
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
TScan Therapeutics has appointed Dr. Dawn Pinchasik as Vice President of Clinical Development. Dr. Pinchasik brings over ten years of experience in clinical development, particularly in gene and cell therapies. This appointment comes as TScan moves forward with its clinical-stage pipeline for hematologic malignancies and solid tumors. The company anticipates dosing its first patient in a Phase 1 study of a solid tumor therapy in the first quarter of 2024.
Read more →TCRXTScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
TScan Therapeutics has appointed Jason A. Amello as its new Chief Financial Officer, bringing nearly 30 years of experience in the biotechnology sector. His appointment comes at a strategic time for the company as it advances its clinical programs in T cell receptor-engineered therapies for cancer treatment. TScan has recently achieved positive initial data from its Phase 1 heme program and secured IND clearances for solid tumors, which positions the company favorably for future growth. Amello's extensive background in financial management is expected to support TScan's operational and strategic goals.
Read more →TCRX▼ -9.6%on this news
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan Therapeutics, Inc. has announced that an abstract highlighting early results from its ongoing Phase 1 study of TCR-engineered therapies TSC-100 and TSC-101 has been accepted for oral presentation at the upcoming Tandem Meetings in San Antonio, Texas. The presentation will focus on their effectiveness in treating residual disease after hematopoietic cell transplantation. The company received a Best Abstracts Award, reflecting the significance of their findings in the field of cancer treatment. This meeting is scheduled for February 21-24, 2024.
Read more →TCRXTScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
TScan Therapeutics has announced its clinical plans for 2024, highlighting positive results from its Phase 1 heme malignancies program presented at the ASH Annual Meeting. The company has achieved complete donor chimerism and minimal residual disease negativity in all six treated patients. TScan also cleared INDs for four TCR-Ts and closed a public offering generating $140.6 million to fund operations into 2026. Additionally, the company aims to initiate a solid tumor clinical study in early 2024 and is collaborating with Amgen on Crohn's Disease targets.
Read more →TCRX▼ -9.1%on this news· ran to -24% by day 3
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65 th American Society of Hematology Annual Meeting and Exposition No relapses have occurred in six of six treatment-arm patients
TScan Therapeutics presented promising initial results for its Phase 1 clinical trial of TSC-100 and TSC-101 at the ASH Annual Meeting. Six patients in the treatment arms showed no relapses, and complete donor chimerism was maintained. In contrast, several patients in the control arm experienced relapses and required interventions. All patients reached the highest dose level without any dose-limiting toxicities, suggesting a solid safety profile as the company plans future expansions.
Read more →TCRXTScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
TScan Therapeutics has appointed R. Keith Woods to its Board of Directors, bringing over 30 years of experience in commercialization and global operations to the company. Known for successfully transitioning argenx into a fully integrated biotech organization, Woods aims to leverage his expertise to support TScan's clinical programs. His previous roles include significant leadership positions at major biopharmaceutical companies, where he was instrumental in product launches and sales strategy.
Read more →TCRX▼ -5.6%on this newsshared move
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
TScan Therapeutics has appointed Justin McCue, Ph.D., as its new Chief Technology Officer. Dr. McCue brings over 20 years of experience in biologics and cell therapy manufacturing, which is anticipated to support TScan's clinical and commercial efforts. His previous roles included leading technology development at Avectas and overseeing CMC development at Repertoire Immune Medicines. TScan is focused on advancing its T cell receptor-engineered therapies for cancer treatment.
Read more →TCRX▼ -5.6%on this newsshared move
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
TScan Therapeutics announced a virtual key opinion leader event scheduled for December 11, 2023, to discuss highlights from its presentation at the 65th ASH Annual Meeting. The focus will be on the company's lead TCR-engineered therapies, TSC-100 and TSC-101, which target HA-1 and HA-2 respectively for treating hematologic malignancies. Featured speakers include prominent figures from TScan and the hematology field, who will review the significance of these therapies for patients undergoing allogeneic hematopoietic cell transplantation.
Read more →TCRX▲ +13%on this newsshared move
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
TScan Therapeutics has been named one of the Top Places to Work in Massachusetts for the second consecutive year, as recognized by The Boston Globe. The ranking is based on employee feedback regarding various workplace factors, including management and benefits. TScan focuses on developing T cell therapies for cancer treatment and emphasizes its employee-centric culture as a key factor in achieving this honor. Their CEO and Senior VP of HR expressed pride in the team's dedication and the supportive workplace environment.
Read more →TCRXTScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Company to present poster on initial data from heme malignancies Phase 1 trial at the 65 th ASH Annual Meeting and Exposition;
TScan Therapeutics has reported its third quarter financial results for 2023, highlighting FDA clearance for the IND of TSC-203-A0201 and upcoming presentations at the ASH Annual Meeting. The company ended the quarter with a strong cash position of $215.4 million, projected to fund operations into 2026. Significant advancements are expected in both their heme and solid tumor clinical programs, with interim data reporting anticipated by year-end. The financial results include a net loss of $23 million, showing an increase compared to the previous year.
Read more →TCRX▲ +11%on this newsshared move
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
TScan Therapeutics presented its Phase 1 trial design for a solid tumor program at the SITC 38th Annual Meeting. The program aims to utilize multiplexed, engineered T cell receptor therapies to address tumor heterogeneity and HLA loss. The company plans to enhance its ImmunoBank to aid in patient screening and treatment customization. TScan is also on track to file IND applications for new TCR-T therapies targeting novel cancer antigens by the end of the year.
Read more →TCRX▲ +7.7%on this newsshared move
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics announced that its abstract has been accepted for a poster presentation at the 65th American Society of Hematology Annual Meeting scheduled for December 9-12, 2023, in San Diego. The presentation will cover initial results from a Phase 1 trial of the engineered T cell therapies TSC-100 and TSC-101, aimed at preventing relapse after hematopoietic cell transplantation. Additionally, the company will host a virtual event to discuss the data following the presentation.
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
TScan Therapeutics announced that six abstracts have been accepted for presentation at the 38th Society for Immunotherapy of Cancer Annual Meeting, scheduled for November 1-5, 2023. The presentations will cover various T cell receptor-engineered therapies aimed at treating solid tumors and hematologic malignancies. This highlights TScan's ongoing commitment to advancing cancer treatment through innovative therapies. Details on the presentations, including topics and timing, have been provided in the announcement.
Read more →TCRX▲ +11%on this news
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TScan Therapeutics has received FDA clearance for its investigational new drug application for TSC-203-A0201, a T cell receptor-engineered therapy targeting PRAME. This therapy is relevant for a significant percentage of melanoma and solid tumor patients, particularly those with HLA type A*02:01. TScan plans to initiate clinical trials under a master protocol, combining this therapy with other agents to tailor treatments to individual patients' tumor profiles. The company aims to deliver treatments to patients with high unmet medical needs and expects to report preliminary clinical data by the end of 2023.
Read more →TCRXTScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26 th Annual Meeting; expect to reach r
TScan Therapeutics has presented preliminary Phase 1 clinical data for its TCR-T therapy candidates, TSC-100 and TSC-101, at the ASGCT Annual Meeting, reporting no dose limiting toxicities. The company received FDA clearance for its TSC-200-A0201 IND application, expanding its solid tumor treatment options. Despite these advancements, TScan reported a net loss of $24 million for Q2 2023 and a decline in revenue year-over-year. The company is well-funded through public offerings and collaborations, anticipating continued progress in its clinical studies.
Read more →TCRXTScan Therapeutics Announces Transition of Chief Financial Officer
TScan Therapeutics announced that Chief Financial Officer Brian M. Silver will leave the company effective July 21, 2023, to pursue a new opportunity. Silver has played a crucial role in the company's financial strategies and operations, and will continue to offer strategic advice. In light of this transition, TScan has initiated a search for a new CFO while expressing appreciation for Silver's contributions. The company remains optimistic about its future clinical milestones and financial standing.
Read more →TCRXTScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
TScan Therapeutics announced FDA clearance for its investigational new drug application for TSC-200-A0201, which targets human papillomavirus 16 (HPV16) associated with certain solid tumors. This marks the third TCR therapy cleared for clinical development within TScan's ImmunoBank program. The T-Plex system allows for customized combinations of TCR therapies tailored to patients' tumor profiles. Initial data for TSC-200-A0201 is expected by the year's end as TScan continues to build its ImmunoBank and anticipates more IND filings in the near future.
Read more →TCRXTScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
TScan Therapeutics, Inc. announced it will present a Trial in Progress (TIP) poster at the 2023 American Society of Clinical Oncology Annual Meeting. The poster will detail the product characteristics and clinical trial design for its T-Plex therapy, aimed at treating solid tumors. The presentation is scheduled for June 3, 2023, and reflects the company's commitment to developing advanced T cell receptor-engineered therapies for cancer. Details of the poster will be made available on the company's website after the session concludes.
Read more →TCRXTScan Therapeutics Announces Closing of Public Offering
TScan Therapeutics has announced the successful closing of a public offering of 23,287,134 shares of common stock at $2.00 per share, raising approximately $140.6 million in gross proceeds. The funds will be used for general corporate purposes, allowing the company to support its operations through 2026. The offering included pre-funded warrants for additional shares, underlining interest from investors. Morgan Stanley and Wedbush PacGrow served as the joint book-running managers for the offering.
Read more →TCRXTScan Therapeutics to Participate in the Jefferies Healthcare Conference
TScan Therapeutics, Inc. announced its upcoming participation in the Jefferies Healthcare Conference, scheduled for June 8, 2023. The company will engage in a fireside chat, which emphasizes its role in advancing T cell receptor-engineered therapies for cancer treatment. TScan's lead therapy candidates are focused on addressing hematologic malignancies, and the event will be webcast for broader access.
Read more →TCRX▲ +31.3%on this newsshared move
TScan Therapeutics Announces Pricing of $140 Million Public Offering
TScan Therapeutics has announced the pricing of an underwritten public offering, raising approximately $140 million by offering nearly 23 million shares at $2.00 each. The company plans to allocate the proceeds towards general corporate purposes and anticipates that it will fund its operational needs through 2026. The offering is set to close in late May 2023 and includes a provision for underwriters to purchase additional shares. This funding comes as TScan continues to develop its advanced T cell receptor-engineered therapies for treating various cancers.
Read more →TCRXTScan Therapeutics Announces Launch of Proposed Public Offering
TScan Therapeutics has announced a proposed public offering of shares, including voting and non-voting common stock. The company aims to use the proceeds from this offering for general corporate purposes. The proposed offering is managed by Morgan Stanley and Wedbush PacGrow, and the underwriters have a 30-day option to purchase additional shares. However, completion of the offering depends on market and regulatory approval.
Read more →TCRXTScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors WALTHAM, Mass., May 24 , 2023 TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage bioph
TScan Therapeutics has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and a member of the Board of Directors, effective May 24, 2023. Previously the acting CEO since March, Dr. MacBeath has been with TScan since 2018, advancing its clinical programs in TCR-engineered T cell therapies. His leadership has notably expanded TScan's initiatives beyond oncology, including a collaboration with Amgen focused on Crohn's disease. The Board expressed strong confidence in his ability to guide TScan's growth and development as they continue to innovate in treatment options for cancer patients.
Read more →TCRX▼ -10.5%on this news
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting Poster highlights Phase 1 results following treatment with TSC-10
TScan Therapeutics presented preliminary Phase 1 clinical trial results for its TCR-engineered T cell therapies, TSC-100 and TSC-101, at the ASGCT 26th Annual Meeting. The trial focuses on treating patients with residual disease post-hematopoietic cell transplantation for blood cancers like AML, MDS, and ALL. Notable outcomes include T cell expansion and high donor chimerism in treated patients without significant toxicities. The company aims to accelerate the development of these therapies with further results expected by the end of 2023.
Read more →TCRX▲ +42.6%on this news
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Entered into partnership with Amgen to identify novel targets in Crohn's disease; TScan to receive $30 million upfront Enrolle
TScan Therapeutics announced positive first quarter 2023 financial results, highlighting a new partnership with Amgen focused on Crohn's disease that provides $30 million upfront. The company is advancing its trials for TCR-engineered therapies, with patient enrollment completed for multiple study arms. Despite increased operational expenses and a reported net loss, TScan's cash position of $95.6 million ensures funding into the third quarter of 2024. Moreover, they are set to present at the upcoming ASGCT meeting, reflecting ongoing engagement in the therapeutic space.
Read more →TCRX▲ +51.1%on this news· ran to +116% by day 1shared move
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN S DISEASE Collaboration Brings Together TScan s Proprietary Target Discovery Platform and Amgen s Inflammation Therapeut
Amgen and TScan Therapeutics have announced a multi-year collaboration aimed at identifying novel targets for Crohn's disease using TScan's TargetScan platform. Under the agreement, TScan will receive an upfront payment of $30 million, with additional potential milestones exceeding $500 million. Amgen will leverage TScan's technology to develop new therapeutics while retaining all global development and commercial rights. There is also an option to extend the collaboration to include ulcerative colitis.
Read more →TCRX▲ +26.2%on this news· ran to +46% by day 3
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
TScan Therapeutics, a clinical-stage biopharmaceutical company, has announced the acceptance of a Trial in Progress poster presentation at the ASGCT 26th Annual Meeting, scheduled from May 16-20, 2023. The presentation will focus on its ongoing Phase 1 umbrella trial of engineered T cell therapies, TSC-100 and TSC-101, which aim to eliminate residual disease in hematopoietic cell transplantation patients. A virtual event will follow on May 17, 2023, to discuss the presentation details and trial updates.
Read more →TCRXTScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors Deepens the Board s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors
TScan Therapeutics has appointed Dr. Barbara Klencke, M.D., to its Board of Directors to bolster its expertise in clinical oncology and commercialization. The company is advancing its clinical pipeline for hematologic malignancies and solid tumors, with several anticipated value inflection points throughout 2023. In addition to Dr. Klencke's appointment, TScan has announced key leadership promotions that aim to strengthen its executive management team as they embark on their clinical trials. These moves reflect the company's commitment to developing life-changing T cell therapies for cancer patients.
Read more →TCRX▼ -18.3%on this news
TScan Therapeutics Announces CEO Transition
TScan Therapeutics has announced a leadership transition with Gavin MacBeath appointed as the acting CEO following David Southwell's resignation. MacBeath, who was previously the Chief Scientific and Operating Officer, has extensive experience in the oncology field. The company reaffirmed its milestones and cash runway while updating on clinical programs, including the dosing of its first patient with TSC-101. TScan aims to further its advancements in T cell receptor-engineered T cell therapies for cancer treatment.
Read more →TCRX▲ +5.8%on this newsshared move
TSCAN THERAPEUTICS ANNOUNCES CEO TRANSITION David Southwell Steps Down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to Serve as Acting CEO Company Reaffirms Previously Disclosed Milestones and Cash Run
TScan Therapeutics has announced a transition in its leadership, with Gavin MacBeath, Ph.D., taking over as acting CEO following the resignation of David Southwell. MacBeath, who has been with the company since 2018, will continue to drive TScan's clinical strategy and research amidst ongoing cancer therapy developments. The company has recently dosed its first patient in a clinical trial and reaffirmed its cash runway, which is projected to sustain operations into the second quarter of 2024. TScan remains committed to advancing its T cell receptor-engineered therapies for cancer treatments.
Read more →TCRXTScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
TScan Therapeutics has announced the dosing of the first patient in its Phase 1 umbrella trial of TSC-100 and TSC-101, targeting minor histocompatibility antigens to treat hematologic malignancies such as acute myeloid leukemia. The trial aims to reduce relapse rates post-hematopoietic cell transplantation in patients who underwent reduced intensity conditioning. The company expressed optimism regarding the potential of their therapies to improve outcomes in this patient population. Additional data from the trial is expected later in 2023, which will provide insights into safety and efficacy compared to standard care.
Read more →TCRX▼ -13.3%on this newsshared move
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
TScan Therapeutics, Inc. announced its participation in the Barclays Global Healthcare Conference, scheduled for March 15, 2023, in Miami Beach, FL. The event will feature a fireside chat that showcases the company's innovations in T cell receptor-engineered therapies for cancer treatment. A webcast of the discussion will be accessible on the company's website, along with an archived replay available for 90 days post-event. This participation underscores TScan's commitment to communication and engagement within the biopharmaceutical community.
Read more →TCRXTScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients int
TScan Therapeutics reported its financial results for Q4 and full year 2022, highlighting significant milestones. The company is advancing its Phase 1 umbrella trial for TSC-100 and TSC-101, expecting to enroll patients and provide a clinical update by mid-2023. With regulatory clearance for key INDs and $120 million in cash, TScan plans to expand its T-cell receptor therapies for solid tumors, while navigating increased operational costs and net losses.
Read more →TCRX▲ +6.8%on this news
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
TScan Therapeutics, Inc. announced its participation in the Cowen 43rd Annual Health Care Conference, scheduled for March 8, 2023. The company specializes in developing T cell receptor-engineered therapies aimed at treating various cancers. In addition to participating in conferences, TScan is advancing its pipeline with therapies designed to address hematologic malignancies and solid tumors, utilizing its custom TCR repository, ImmunoBank.
Read more →TCRXTScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
TScan Therapeutics, Inc. has announced its participation in the H.C. Wainwright Cell Therapy Virtual Conference, scheduled for February 28, 2023. The company, which specializes in T cell receptor-engineered therapies for cancer, will present insights into its ongoing clinical developments. Notably, TScan is advancing TCR-T therapies aimed at treating hematologic malignancies and solid tumors. A webcast of the presentation will be accessible for a period of 90 days on the company's website following the event.
Read more →TCRXTScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to creat
TScan Therapeutics has received FDA clearance for three Investigational New Drug Applications, supporting its T-Plex solid tumor program. This allows the simultaneous use of multiple T-cell receptor therapies tailored to individual patients. The approved INDs include TSC-204-A0201 and TSC-204-C0702, targeting the MAGE-A1 antigen in various cancers. The company plans to initiate a Phase 1 clinical trial to assess the safety and efficacy of these therapies later in 2023.
Read more →TCRXTScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
TScan Therapeutics has outlined its clinical plans for 2023, focusing on progressing its T cell receptor-engineered therapies for cancer treatment. The company is set to begin enrollment for its Phase 1 trial targeting hematologic malignancies and has secured IND approvals for several new therapeutic candidates. Additionally, TScan is advancing its solid tumor program and expects to report clinical milestone data by the year's end. The company is well-funded, with resources projected to sustain operations through mid-2024.
Read more →TCRXTScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
WALTHAM, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRX▲ +7.8%on this news
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies Multiplexing TCRs for MAGE-A1 and PRAME demonstrates synergistic cytotoxicity in vitro and in mouse xenograft models Company continues to discover TCRs for its ImmunoBank, enabling customized multiplexed TCR-T
Read more →TCRXTScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tu
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, a
Read more →TCRXTScan Therapeutics Announces Upcoming Virtual Investor Event
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development o
Read more →TCRX▲ +8.6%on this newsshared move
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announce
Read more →TCRXTScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures Financing supports management s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche exten
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures Financing supports management s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, M
Read more →TCRX▲ +12.1%on this newsshared move
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announce
Read more →TCRX▼ -9.9%on this news
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundat
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effe
Read more →TCRXTScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for C*07:02-restricted epitope on MAGE-A1 forms the basis of TScan’s TSC-204-C07 TCR-T therapeutic ca
Read more →TCRXTScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer
WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRX▲ +5.3%on this news
TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies Study start-up activities now ongoing for all three arms of the Phase 1 umbrell
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101 WALTHAM, Mass., May 31, 2022 TSca
Read more →TCRX▼ -14.8%on this news
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22 TCR directed to a novel C*07:02-restricted epitope of MAGEA1, TSC-204-C07, on track for IND submission in 2H22 Multiplexing TCRs in vit
Read more →TCRX▲ +15.9%on this news· ran to +30% by day 1shared move
TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRXTScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRX▼ -8.3%on this newsshared move
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones Preclinical data to be presented at the American Society of Gene & Cell Therapy 25 th Annual Meeting; virtual KOL event
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones Preclinical data to be presented at the American Society of Gene & Cell Therapy 25th Annual Meeting; virtual KOL event following the conference Phase 1 umbrella trial for leukemi
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting
WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced
Read more →TCRX▲ +17.8%on this news
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announce
Read more →TCRX▲ +5.4%on this news
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tum
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expect
Read more →TCRXTScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Compa
Read more →TCRX▼ -5.2%on this news
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies - Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 - IND
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies - Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 - IND for TSC-101 on hold pending additional assessment of the
Read more →TCRX▼ -8.3%on this news
TScan Outlines 2022 Priorities as Programs Enter Clinic
IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101 Lead TCR Identified for Solid Tumor Program Targeting HPV16; Further TCRs Advancing into IND-Enabling Activities with IND Submissions Planned for Second Half of 2022 TSca
Read more →TCRXTScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
- Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 - - Phase 1 clinical trial expected to initiate in the first half of 2021 - - Company to host virtual KOL event Wednesday, Dec. 15 at
Read more →TCRXTScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition
WALTHAM, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Compa
Read more →TCRX▼ -5.7%on this newsshared move
TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies
WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has co
Read more →TCRXTScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Le
TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid-tumor Program Targetin
Read more →TCRXTScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that two abstr
Read more →TCRXTScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations
WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointmen
Read more →TCRXTScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David So
Read more →TCRXTScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Zoran Zd
Read more →TCRXTScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David So
Read more →TCRX▼ -21.2%on this news
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs
TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead
Read more →TCRX▼ -7.1%on this news
TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit
WALTHAM, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Gavin Mac
Read more →TCRXTScan Therapeutics, Inc. Announces Pricing of Initial Public Offering
WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its in
Read more →Competitive Position
How TCRX ranks across every disease it competes inCompetitive Position is a premium feature
See how TCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial